A pH-sensitive β-cyclodextrin-modified periodic mesoporous organosilica hybrid nanomaterial for co-delivery of paclitaxel and curcumin in lung cancer

Abstract

In this study, a novel β-cyclodextrin grafted to 3-aminopropyl and incorporated in the periodic mesoporous organosilica structure (β-CD-APTS-PMO) was prepared via a co-condensation and sequential integration strategy. At first, β-CD-APTS-PMO hybrid nanomaterial was characterized using various techniques including FESEM, FT-IR and EDS spectroscopy, elemental mapping, XRD, TGA, BET, and potential zeta. The β-CD-APTS-PMO hybrid nanomaterial with surface area of 284.35 m2g-1 and average pore diameter of 4.9 nm was developed to evaluate its in vitro antitumor activity. Paclitaxel (PTX) and curcumin (CUR) were successfully co-encapsulated at a pre-optimized ratio in β-CD-APTS-PMO with high encapsulation efficiency (CUR: 90.2 ± 0.56%, PTX: 87.4 ± 0.12%). Paclitaxel and curcumin co-loaded β-CD-APTS-PMO demonstates sustained-release properties in vitro. However, the drug release profile results demonstrated that CUR was released much faster than PTX. The release of CUR in advance would allow effective chemosensitization of cancer cells, which in turn would increase the therapeutic efficacy of PTX. The results of MTT study indicate that paclitaxel and curcumin co-loaded β-CD-APTS-PMO had a better anticancer effect than free paclitaxel or curcumin. These results indicate that β-CD-APTS-PMO is a promising candidate for the lung cancer combination therapy.